The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression https://t.co/iz8iJTBNGQ A definitive overview of these useful but neglected therapies
The 'Prescriber's Guide to MAOIs' - the first ever expert consensus guideline on the use of phenelzine, tranylcypromine, isocarboxazid in treatment-resistant depression - has been published and is available open access at https://t.co/KWcuDr4Xds! @APApsychiatric@Euro_Psychiatry
Het #euthanasiedebat is nog steeds zeer actueel. Onze nieuwste publicatie "Euthanasierecht in België. De wet in verandering (?)" verzamelt essays en kanttekeningen van zowel voor- als tegenstanders. Het boek is nu te koop via onze webshop 👉 https://t.co/RBfT9Gi70H.
Classic monoamine oxidase inhibitors are potent antidepressants that have fallen unjustly into disrepute. A concerted effort is required to restore ample availability, & proper use in psychiatric practice, of these life-saving medications. https://t.co/WZSOCj3TdQ
@VincentEynde
Shortages have devastating effects, no doubt about that! A report from the trenches: On the limited availability of classic MAOIs in Belgium: the “call for action” extended https://t.co/5SfVCKt5IB
Monoamine Oxidase Inhibitors (MAOIs) are effective (albeit oft-overlooked) antidepressants. Consider sharing the MAOI group statement "Revitalizing monoamine oxidase inhibitors: a call for action": https://t.co/tTdPD5SS6J
#antidepressants#pharmaindustry#depression#Psychiatry
Tranylcypromine, a classic monoamine oxidase inhibitor (MAOI), has a - shamefully overlooked - place in the pharmacotherapy of depression #antidepressants#pharmaindustry#psychiatry
Tranylcypromine and TCAs have an equal antidepressant effect in depressed patients with mixed psychomotor symptoms but, Tranylcypromine might be superior to TCAs in depression with predominant psychomotor retardation https://t.co/Og4iWHTHGy